Pfizer Inc PFE:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 2:28 PM EST

43.45

-0.30 (-0.70%)

Volume

12,686,187

52 week range

41.45 - 56.32

Open43.82
Day High43.90
Day Low43.25
Prev Close43.76
52 Week High56.32
52 Week High Date04/11/22
52 Week Low41.45
52 Week Low Date10/11/22

Key Stats

Market Cap243.926B
Shares Out5.613B
10 Day Average Volume27.76M
Dividend1.64
Dividend Yield3.77%
Beta0.61
YTD % Change-15.12

KEY STATS

Open43.82
Day High43.90
Day Low43.25
Prev Close43.76
52 Week High56.32
52 Week High Date04/11/22
52 Week Low41.45
52 Week Low Date10/11/22
Market Cap243.926B
Shares Out5.613B
10 Day Average Volume27.76M
Dividend1.64
Dividend Yield3.77%
Beta0.61
YTD % Change-15.12

RATIOS/PROFITABILITY

EPS (TTM)5.47
P/E (TTM)7.94
Fwd P/E (NTM)11.84
EBITDA (TTM)42.308B
ROE (TTM)35.91%
Revenue (TTM)100.331B
Gross Margin (TTM)65.52%
Net Margin (TTM)31.30%
Debt To Equity (MRQ)39.59%

EVENTS

Earnings Date05/01/2023(est)
Ex Div Date01/26/2023
Div Amount0.41
Split Date-
Split Factor-

Latest On Pfizer Inc

U.S. plans to stop buying Covid shots. Here's what that meansFebruary 4, 2023CNBC.com
Pro Picks: Watch all of Tuesday's big stock calls on CNBCJanuary 31, 2023CNBC.com
End of the Covid health emergency won't slow FDA review of shots and treatmentsJanuary 31, 2023CNBC.com
Tuesday, Jan. 31, 2023: Cramer buys more of this stock he says is oversoldJanuary 31, 2023CNBC.com
The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billionJanuary 31, 2023CNBC.com

Content From Our Affiliates

Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)4 Hours AgoTipRanks
Pfizer stock a buy as company moves beyond COVID, Barron’s saysFebruary 4, 2023TipRanks
SVB Securities Sticks to Its Hold Rating for Pfizer (PFE)February 2, 2023TipRanks
FDA revises EUA for Paxlovid to remove SARS-CoV-2 viral testing requirementFebruary 1, 2023TipRanks
Novavax refuses to refund $700M for COVID shots never delivered, NY Times saysFebruary 1, 2023TipRanks

Profile

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global...

Albert Bourla Ph.D.

Chairman of the Board, Chief Executive Officer

David Denton

Executive Vice President, Chief Financial Officer

Aamir Malik

Executive Vice President, Chief Business Innovation Officer

Lidia Fonseca Ph.D.

Executive Vice President